Patents Examined by Michael Schmitt
  • Coumarin derivatives for cancer therapy
    Patent number: 9403791
    Abstract: The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 2, 2016
    Assignee: Wellesley College
    Inventor: Dora Carrico-Moniz
  • Methods for treating HCV
    Patent number: 9393256
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 19, 2016
    Assignee: Gilead Pharmasset LLC
    Inventors: Adrian S. Ray, John O. Link, David W. Oldach, William E. Delaney, IV, Hongmei Mo, Cheng Yong Yang
  • Coumarin derivatives for cancer therapy
    Patent number: 9388155
    Abstract: The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 12, 2016
    Assignee: Wellesley College
    Inventor: Dora Carrico-Moniz
  • Composition and method of treating skin conditions
    Patent number: 9387160
    Abstract: This invention relates to compositions containing a retinoid and use of the compositions for treating skin conditions.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 12, 2016
    Assignee: Johnson & Johnson Consumer Holdings France
    Inventors: Thierry Oddos, Linda Fournier, Gaelle Bellemere, Sébastien Saclier, Anne-Sophie Brillouet
  • Substituted benzimidazoles
    Patent number: 9388140
    Abstract: The present invention relates to substituted benzimidazole compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 12, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Klar, Marcus Koppitz, Duy Nguyen, Dirk Kosemund, Roland Neuhaus, Gerhard Siemeister
  • Benzyl sulfonamide derivatives as RORc modulators
    Patent number: 9382222
    Abstract: Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: July 5, 2016
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Olivier Rene, Monique Bodil van Niel, Simon Gaines, Jonathan Killen, Stuart Ward
  • Inhibitors of cognitive decline
    Patent number: 9365491
    Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: June 14, 2016
    Assignee: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. Rishton, Susan Catalano
  • Compounds and compositions as TLR2 agonists
    Patent number: 9365506
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 14, 2016
    Assignee: NOVARTIS AG
    Inventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
  • Use of Pateamine A for the treatment of age-related muscle wasting
    Patent number: 9358249
    Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: June 7, 2016
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep
  • Dihydropyrimidine compounds and their application in pharmaceuticals
    Patent number: 9340538
    Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 17, 2016
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
  • Clonidine and GABA compounds in a biodegradable polymer carrier
    Patent number: 9301946
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 5, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Jared T. Wilsey, Danielle L. Biggs, Jeffrey C. Marx, William F. McKay, Josee Roy, John Myers Zanella
  • Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma
    Patent number: 9302967
    Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: April 5, 2016
    Assignee: Council of Scientific & Industrial Research
    Inventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Choudhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Pradyot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
  • Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
    Patent number: 9301947
    Abstract: This invention relates to methods of treating T-cell mediated diseases or disorders in human or animal subjects, such as autoimmune diseases and chronic graft versus host disease in humans and animals. In particular, the methods comprise administering to the human or animal patient a pharmaceutical composition comprising a ryanodine receptor inhibitor.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: April 5, 2016
    Assignee: The Regents of the University of California
    Inventor: Alla F. Fomina
  • Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration
    Patent number: 9290464
    Abstract: Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: March 22, 2016
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Cheol Hyoung Park, Hye Kyung Min, In Suk Park, Mi Jung Lim, Ji Won Lee, Jin Yong Chung, Yeo Jin Yoon, Joo Young Park
  • Method of treating dyskinesia
    Patent number: 9289423
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 22, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Mary Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Crystalline forms of (R)-3-[N-(3'-chlorobiphenyl-4-ylmethyl)-N'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl ester
    Patent number: 9271965
    Abstract: The invention provides crystalline forms of (R)-3-[N-(3?-chlorobiphenyl-4-ylmethyl)-N?-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: March 1, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
  • Colchicine solid-state forms; methods of making; and methods of use thereof
    Patent number: 9255063
    Abstract: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: February 9, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Tong Sun, Kurt Nielsen, Shawn Watson, Rolf Hilfiker, Andreas Sieber
  • Use of derivatives of indoles for the treatment of cancer
    Patent number: 9212138
    Abstract: The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: December 15, 2015
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Catherine Guillou, Frank Kozielski, Christophe Labriere, Francoise Gueritte, Sergey Tcherniuk, Dimitrios Skoufias, Claude Thal, Henri-Philippe Husson
  • Treatment regimen utilizing neratinib for breast cancer
    Patent number: 9211291
    Abstract: An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: December 15, 2015
    Assignee: WYETH LLC
    Inventors: Anna Berkenblit, Florence Marie Helene Binlich, Paul Goss
  • Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
    Patent number: 9206175
    Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: December 8, 2015
    Assignee: GENENTECH, INC.
    Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel S. Kintz, Hans Edward Purkey